tradingkey.logo
tradingkey.logo
Search

Eupraxia Doses First Patient In Phase 2B Placebo-Controlled Portion Of Ep-104GI Resolve Trial

ReutersJul 8, 2025 11:28 AM
facebooktwitterlinkedin
View all comments0

- Eupraxia Pharmaceuticals Inc EPRX.TO:

  • EUPRAXIA DOSES FIRST PATIENT IN PHASE 2B PLACEBO-CONTROLLED PORTION OF EP-104GI RESOLVE TRIAL IN EOSINOPHILIC ESOPHAGITIS

  • EUPRAXIA PHARMACEUTICALS INC - TOPLINE DATA FROM PHASE 2B STUDY EXPECTED BY Q3 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI